Synbio Technologies
Suzhou Shi
About Synbio Technologies
Synbio Technologies provides hybridoma antibody gene sequencing, immune repertoire sequencing, antibody design, antibody humanization, monoclonal antibody preparation, polyclonal antibody preparation, preparation of recombinant engineering antibodies, stable cell line construction, plasmid preparation, and point mutation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $17.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2018)
- Ticker: neeq:871854
- Website: synbio-tech.com.cn
- Phone: +861-512-62600336
Industries & Categories
Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/synbio-technologies-202665 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.